Sofosbuvir-Reference-Cited by-同舟云学术

Sofosbuvir

Published:2014-05 Issue:5 Volume:49 Page:466-478
ISSN:0018-5787
Container-title:Hospital Pharmacy
language:en
Short-container-title:Hosp Pharm

Author:

Cada Dennis J.¹,Cong Jasen²,Baker Danial E.³

Affiliation:

1. Washington State University, Spokane, Washington

2. Drug Information Resident, Drug Information Center, Washington State University, Spokane, Washington

3. Drug Information Center, College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, Washington 99210-1495.

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The May 2014 monograph topics are droxidopa, elosulfase alfa, vorapaxar, ramucirumab, and pimavanserin. The DUE/MUE is on droxidopa.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pharmacology,Pharmacy

Link

http://journals.sagepub.com/doi/pdf/10.1310/hpj4905-466

Reference31 articles.

1. Sovaldi [package insert]. Foster City, CA: Gilead Sciences; December 2013.

2. Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C

3. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

4. Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection

5. Sa2073 SVR4 Results of a Once Daily Regimen of Simeprevir (TMC435) Plus Sofosbuvir (GS-7977) With or Without Ribavirin (RBV) in HCV GT 1 Null Responders

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An in vivo and in silico evaluation of the hepatoprotective potential of Gynura procumbens: A promising agent for combating hepatotoxicity;PLOS ONE;2023-09-15

2. Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19;Microorganisms;2022-08-12

3. An in vivo and in silico evaluation of the magical hepatoprotective potentialities of Gynura procumbens: a promising agent for combating hepatotoxicity;2022-05-11

4. Investigation of the effect of verapamil on the regional absorption of sofosbuvir from rabbit intestine in situ;DARU Journal of Pharmaceutical Sciences;2022-01-13

5. Screening of novel drugs for inhibiting hepatitis E virus replication;Journal of Virological Methods;2019-08